Develops and sells cancer medicines, including a treatment for adults with a specific type of lung cancer, and advances other cancer drug candidates.
10-K for FY2025, filed Mar 2, 2026We are a global oncology company focused on tackling some of the toughest challenges in cancer treatment with the goal of developing…View ↗
We commercially launched IBTROZI in the U.S. in June 2025, following its approval by the U.S. Food and Drug Administration (“FDA”) on June…View ↗
In addition to taletrectinib, our clinical stage pipeline includes safusidenib, a novel, oral, potent, brain penetrant, targeted inhibitor…View ↗
Licensing and collaboration agreements are the larger revenue stream: partners pay upfront and milestone fees, royalties tied to sales and for research services; U.S. customers buy shipped IBTROZI.
10-K for FY2025, filed Mar 2, 2026The Company enters into collaborative arrangements for the research and development, and commercialization of drug products and drug…View ↗
In May 2021, AnHeart entered into an agreement with Innovent, granting Innovent a sub-licensable, royalty-bearing, exclusive right and…View ↗
For the year ended December 31, 2025, the Company recognized research and development service revenue of $5.3 million, sales of products…View ↗
Net product revenue was approximately $24.7 million for the year ended December 31, 2025 from the U.S. sales of IBTROZI. We began shipping…View ↗
$62.9M
10-K for FY2025, filed Mar 2, 2026
$62.9M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product Revenue
Sold outright
10-K for FY2025, filed Mar 2, 2026 |
39% |
Product Revenue, FY2025
$24.7M Sources
|
Sold outright |
|
License
Licensed
10-K for FY2025, filed Mar 2, 2026 |
61% |
License, FY2025
$38.2M Sources
|
Licensed |
U.S. customers buy IBTROZI from Nuvation Bio; partners Innovent and Nippon Kayaku commercialize taletrectinib in China and Japan.
10-K for FY2025, filed Mar 2, 2026We commercially launched IBTROZI in the U.S. in June 2025, following its approval by the U.S. Food and Drug Administration (“FDA”) on June…View ↗
Net product revenue was approximately $24.7 million for the year ended December 31, 2025 from the U.S. sales of IBTROZI. We began shipping…View ↗
In May 2021, AnHeart entered into an agreement with Innovent, granting Innovent a sub-licensable, royalty-bearing, exclusive right and…View ↗
In October 2023, AnHeart entered into an agreement with NK, granting NK a sub-licensable, royalty-bearing, exclusive right and license to…View ↗
No. It lost $204.6M in FY2025.
10-Q for Q3 FY2026, filed Nov 4, 2026
−$41.9MView ↗
10-Q for Q3 FY2026, filed Nov 4, 2026
Open tableView ↗
From development to sales
The earlier report described Nuvation as clinical-stage and focused on candidates; the latest describes a U.S. launch of IBTROZI and commercial operations.
10-K for FY2022, filed Mar 15, 2023 10-K for FY2025, filed Mar 2, 2026We are a clinical-stage biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and…View ↗
Pipeline focus
The earlier report highlighted an oncology candidate and a drug-conjugate program; the latest centers its clinical pipeline on taletrectinib and safusidenib, while continuing preclinical drug-conjugate work.
10-K for FY2022, filed Mar 15, 2023 10-K for FY2025, filed Mar 2, 2026Taletrectinib continues to be evaluated for the treatment of patients with locally advanced or metastatic ROS1+ NSCLC in two Phase 2…View ↗
In addition to taletrectinib, our clinical stage pipeline includes safusidenib, a novel, oral, potent, brain penetrant, targeted inhibitor…View ↗
Advancing the ongoing clinical development of safusidenib and continued evaluation of preclinical candidates from our drug-drug conjugate…View ↗
Territorial partnerships
The earlier report said it held worldwide development and commercial rights and planned to consider collaborations; the latest describes partners commercializing taletrectinib in China and Japan and a partnership with Eisai for Europe.
10-K for FY2022, filed Mar 15, 2023 10-K for FY2025, filed Mar 2, 2026Evaluate strategic opportunities to accelerate development timelines and maximize value of our product candidate pipeline. We currently own…View ↗
We commercially launched IBTROZI in the U.S. in June 2025, following its approval by the U.S. Food and Drug Administration (“FDA”) on June…View ↗
Competes with AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer, Regeneron Pharmaceuticals, Sanofi, Roche, Nuvalent, Servier, and Rigel
10-K for FY2025, filed Mar 2, 2026We compete in the segments of the pharmaceutical, biotechnology and other related markets that develop small molecules and drug conjugates…View ↗
Loading...